Reaction
Bladder Transitional Cell Carcinoma reporting signals
As of the last recalculation, Bladder Transitional Cell Carcinoma appears in 1,415 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is PIOGLITAZONE (PRR 294.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pioglitazone | 538 | 294.7 | 298.4 |
| Ampicillin | 25 | 45.2 | 45.3 |
| Ampicillin Sodium | 25 | 45.2 | 45.3 |
| Amphotericin B | 20 | 23.8 | 23.8 |
| Nebivolol | 23 | 21.6 | 21.6 |
| Sirolimus | 19 | 21.0 | 21.0 |
| Prednisolone Acetate | 14 | 20.1 | 20.1 |
| Glipizide | 77 | 19.6 | 19.6 |
| Desoximetasone | 23 | 18.0 | 18.1 |
| Mometasone | 22 | 17.9 | 17.9 |
| Trimethoprim | 14 | 17.6 | 17.7 |
| Sitagliptin | 76 | 16.3 | 16.3 |
| Terazosin Hydrochloride | 9 | 15.0 | 15.0 |
| Chlorthalidone | 10 | 12.8 | 12.8 |
| Sulfasalazine | 64 | 12.6 | 12.6 |
| Glyburide | 20 | 12.3 | 12.3 |
| Baricitinib | 7 | 10.7 | 10.7 |
| Nebivolol Hydrochloride | 24 | 10.6 | 10.6 |
| Doxazosin Mesylate | 25 | 10.4 | 10.4 |
| Minoxidil Foam 5% (Womens) | 22 | 9.9 | 10.0 |
| Metformin Hcl | 36 | 9.8 | 9.8 |
| Metformin Er 500 Mg | 174 | 9.6 | 9.6 |
| Metformin Er 750 Mg | 174 | 9.6 | 9.6 |
| Glimepiride | 20 | 7.6 | 7.6 |
| Minoxidil | 22 | 7.3 | 7.3 |
| Apalutamide | 5 | 6.3 | 6.3 |
| Liraglutide | 16 | 4.8 | 4.8 |
| Exenatide | 17 | 4.8 | 4.8 |
| Ravulizumab | 4 | 4.4 | 4.4 |